Toshihiro Kudo

Toshihiro Kudo

Auto-generated profile, based on publicly available information

Toshihiro Kudo

19Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TKTakeshi Kato
Takeshi Kato
TKToshihiro Kudo
Toshihiro Kudo
YKYoshinori Kagawa
Yoshinori Kagawa
KMKohei Murata
Kohei Murata
HOHirofumi Ota
Hirofumi Ota
HEHidetoshi Eguchi
Hidetoshi Eguchi
Regorafenib has shown significant survival benefit as a salvage therapy for colorectal cancer; however, its starting dose has been controversial in recent studies. Therefore, we conducted a prospective study on the efficacy and safety of the dose reduction of regorafenib to 120 mg. Patients received 120 mg regorafenib once per day for 3 weeks, followed by a 1-week off-treatment period. The primary endpoint was the investigator-assessed disease control rate (DCR). Sixty patients were registered, and the DCR was 38.3% with a median progression-free survival of 2.5 months (95% confidence interval [CI] 1.9–3.7) and median overall survival of 10.0 months (95% CI 6.9–15.2). Common grade 3–4 adverse events were hand-foot skin reaction and hypertension (20.0% each). The results of administration of 120 mg regorafenib as the starting dose are consistent with reports from prior phase III trials, which used starting doses of 160 mg. This lower initiating dose of regorafenib may be beneficial to certain patient populations. This clinical trial was registered in the UMIN Clinical Trials Registry (UMIN-CTR number UMIN000018968, registration date: 10/09/2015).

2 July 2019 in Oncology
Verified
Journal Article
Closed access
PDF file
TKToshihiro Kudo
Toshihiro Kudo
ITIchiro Takemasa
Ichiro Takemasa
THTsuyoshi Hata
Tsuyoshi Hata
DSDaisuke Sakai
Daisuke Sakai
HTHidekazu Takahashi
Hidekazu Takahashi
YDYuichiro Doki
Yuichiro Doki
Objectives: The aim of this study was to determine the recommended dose (RD) of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer. Method: Patients received irinotecan and oxaliplatin (85 mg/m2) on day 1, and capecitabine (1,000 mg/m2 orally twice daily) on days 1–7 of a biweekly schedule. Three dose levels, ranging from 100 to 150 mg/m2, were explored for irinotecan in sequential cohorts of 6 patients. Dose-limiting toxicities (DLTs) were assessed in the first cycle to determine the RD. Results: Six patients were enrolled. The DLT was grade 3 febrile neutropenia, which was observed in 2 of the 6 patients at dose level 1. The RD of irinotecan was defined as 150 mg/m2. Toxicity was manageable: the most common grade ≥3 toxicities were neutropenia (2 patients), anemia (1 patient), and anorexia (1 patient). Nodal downstaging (cN+ to ypN0) was detected in 2 patients and the T stage was downstaged in 3 patients. Conclusions: XELOXIRI is a feasible and active regimen for patients with locally advanced rectal cancer. Febrile neutropenia was the DLT, and the RD of irinotecan is 150 mg/m2.

27 November 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YIYasunobu Ishizuka
Yasunobu Ishizuka
TOTakeshi Omori
Takeshi Omori
NSNaoki Shinno
Naoki Shinno
MYMasaaki Yamamoto
Masaaki Yamamoto
HHHisashi Hara
Hisashi Hara
TKToshihiro Kudo
Toshihiro Kudo
Brain metastases develop in 0.5–0.7% of patients with gastric/gastroesophageal junction (G/GEJ) cancer. Although rare, brain metastasis is often identified when the patient is already symptomatic; hence prognosis is poor. Given the therapeutic developments for G/GEJ cancer, overall survival is prolonged, thereby the incidence of brain metastases is predicted to increase. We retrospectively surveyed the rate of brain metastasis among 1257 patients diagnosed with G/GEJ cancer who received chemotherapy between January 2011 and April 2021. We investigated the time of onset of brain metastasis, treatments administered, and impact of the metastasis on the overall treatment course and prognosis. Of the 741 patients included in the analysis, brain metastasis was confirmed in 16 (2.2%). The median survival time (MST) from G/GEJ cancer diagnosis was 14.9 months in patients with brain metastasis detected during the treatment period, and the MST from the diagnosis of brain metastasis was 2.8 months. Patients who received chemotherapy exhibited prolonged survival compared with those who did not (12.4 months vs 1.0 months, p < 0.001). Our findings suggest that the early detection of brain metastases and local therapy for poor responders to chemotherapy enable the continuation of chemotherapy and prolong survival.

29 August 2024 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
Atsuo TakashimaAtsuo Takashima
Atsuo Takashima
MIMegumi Ishiguro
Megumi Ishiguro
KSKeita Sasaki
Keita Sasaki
RMRyunosuke Machida
Ryunosuke Machida
FNFumio Nagashima
Fumio Nagashima
C(Colorectal Cancer Study Group (CCSG) of the Japan Clinical Oncology Group (JCOG)
Colorectal Cancer Study Group (CCSG) of the Japan Clinical Oncology Group (JCOG)
Although treatment outcomes for metastatic colorectal cancer (mCRC) have dramatically improved over the past few decades, drug costs have also significantly increased. This study aimed to investigate which first-line treatment regimens for mCRC are actually used (frequency) in Japanese practice and at what cost. We collected data on patients with mCRC who received first-line treatment at 37 institutions of the Japan Clinical Oncology Group Colorectal Cancer Study Group from July 2021 to June 2022, and calculated the cost of regimens. The cost per month of each regimen was estimated based on standard usage, assuming a patient with a weight of 70 kg and a body surface area of 1.8 m2. We categorized the regimens into very high-cost (≥1 000 000 Japanese yen [JPY]/month), high-cost (≥500 000 JPY/month), and others (500 000JPY/month, and molecular targeted drugs being the main drivers of cost.

11 November 2020 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TKToshihiro Kudo
Toshihiro Kudo
YMYoshiyuki Murai
Yoshiyuki Murai
YKYoshitsugu Kojima
Yoshitsugu Kojima
KUKenji Uehara
Kenji Uehara
TSTaroh Satoh
Taroh Satoh
Objective: This phase 2 study examined the efficacy and safety of tolvaptan, an aquaretic drug, in the treatment of ascites associated with cancer. Methods: In the dose-escalation phase, oral tolvaptan was initiated at a dose of 3.75 mg/day, and the dose was increased daily to 7.5, 15 and 30 mg/day. Dose escalation was terminated once the increase from baseline in the daily urine volume reached 500 ml, at which point the patient proceeded to the maintenance phase of 5–7 days. Improvement of ascites was determined primarily by reduction in body weight and ascitic fluid volume. Results: The mean change from baseline in body weight was maintained below 0 kg throughout the study. The mean change (±standard deviation) from baseline in ascitic fluid volume at the end of treatment (EOT) was 237.45 ± 868.14 ml in 33 evaluable patients. Although an increase from baseline in ascitic fluid volume at the EOT was observed in 23 of 33 patients (maximum: 1589.3 ml, minimum: 3.83 ml), a reduction in ascitic fluid volume was observed in the remaining 10 patients (maximum: −2304.3 ml, minimum: −27.5 ml). The common treatment-emergent adverse events included vomiting (5 of 43 patients, 11.6%), abdominal distension, constipation, thirst, blood osmolarity increased and renal impairment (3 of 43 patients, 7.0% each). Conclusions: Tolvaptan seemed to have no definitive effect on reducing ascites; however, it might be effective in at least some cancer patients. No new safety concerns were identified at doses of 3.75–30 mg/day.

2 June 2025 in Oncology Letters
Verified
Journal Article
Open access
PDF file
YKYoshiki Kojitani
Yoshiki Kojitani
DSDaisuke Sakai
Daisuke Sakai
TOTakatsugu Ogata
Takatsugu Ogata
YAYumi Amano
Yumi Amano
RMRyota Mori
Ryota Mori
TKToshihiro Kudo
Toshihiro Kudo
Metastatic colorectal cancer (mCRC) presents notable therapeutic challenges. Rat sarcoma virus (RAS) mutations, including those in KRAS exon 2, are critical for treatment decisions; however, the role of minor RAS mutations (KRAS exons 3 and 4, and NRAS) remains underexplored. Because these mutations are increasingly identified in routine practice due to advances in RAS mutation testing that now routinely includes KRAS exons 3 and 4, and NRAS, clarifying their clinical relevance has become important for ensuring appropriate treatment selection. The present study aimed to compare the clinical and prognostic characteristics of patients with mCRC with minor RAS mutations to those with KRAS exon 2 mutations. To this end, data were retrospectively collected from patients with mCRC and RAS mutations between August 2018 and December 2023. Patients were grouped based on RAS mutation subtype: KRAS exon 2 or minor RAS mutations. RAS mutation testing was performed using the MEBGEN RASKET™‑B kit. Clinical characteristics, tumor location, metastatic patterns and survival outcomes were analyzed. Overall survival (OS) and progression‑free survival (PFS) were assessed using Kaplan‑Meier survival analysis, log‑rank tests and Cox proportional hazards regression models. Of 202 patients with RAS mutations, 170 had KRAS exon 2 mutations, whereas 32 exhibited minor RAS mutations (20 with non‑exon 2 KRAS mutations and 12 with NRAS mutations). Minor RAS mutations were more common in left‑sided CRC. No significant differences in background were observed between the two groups. Log‑rank OS was comparable for patients with KRAS exon 2 and minor RAS mutations. OS and PFS with first‑line bevacizumab‑containing therapy were also similar between the two groups. In conclusion, the prognostic impact of minor RAS mutations appears to be comparable to that of KRAS exon 2 mutations, suggesting that the current treatment strategies for RAS‑mutant CRC may not require modification based on these findings.